You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

351 Results
Guidelines and Advice
Status: Archived
ID: 6-8
Version: 3
Mar 2015
Guidelines and Advice
Status: Current
ID: GL 6-A-2023-1
Version: 2
Updated
Jan 2026
Guidelines and Advice
Status: Current
ID: GL-END-C50-35
Aug 2023
Guidelines and Advice
Status: Current
ID: MOTAC-6
Version: 2
Sep 2020
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Guidelines and Advice
Status: Current
ID: GL 6-20
Version: 2
May 2023
Guidelines and Advice
Status: Current
ID: SCT-7
Sep 2015
Guidelines and Advice
Status: In-Review
ID: 19-6
Apr 2016
Guidelines and Advice
Status: Archived
ID: 6-18
Version: 2
Jun 2016
Guidelines and Advice
Status: Education and Information
ID: 6-16 Version 2
Version: 2
Feb 2014
Guidelines and Advice
Status: Education and Information
ID: 6-6 Version 2
Version: 2
Jan 2012

Pages